ORA Newsletter - Week ending 02/08/02
Please note that if a link breaks across lines, you will need
to copy both lines of the link and paste it into your browser window to access
the page. To print a viewable copy of this newsletter, you must go to
page-set up and change you page orientation to landscape. According to your
printer you may also need to change your margins. Otherwise you may print the
sections directly from the ORA website.
Section 1 – What’s New
Section 2 – New Funding Opportunities
Section 3 – Conferences
Section 4 – Reminders
Section 5 – Closing Information and Unsubscribe Instructions
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»
1) 2002
UFRF Professorships.
Vice President
Phillips has announced the selection criteria for 2002 UFRF Professorships.
The College of Medicine will be able to select 5 professorships to be
awarded. Our
timeline for nomination and selection is tight so please give this immediate
attention. Nominations should come to the Office for Research Affairs,
M-134, by 5pm on February 22, 2002. As you know this is a three-year term
award that is accompanied by a $5,000 annual supplement and a one-time $3,000
grant to support research.
Associate and Full
Professors who are tenured and have been on the UF faculty for at least 5 years
are eligible. Faculty are eligible for nomination following a two-year
hiatus after holding a previous UFRF Professorship. (Anyone funded in
1997 or before will become eligible again.)
Candidates must have a distinguished CURRENT research program that places them among the leaders in their discipline. This is measured over the last five years. The work must also indicate that the program is likely to lead to continuing distinction in his/her field.
Examples of objective criteria include:
· Citation analysis, where appropriate
All Nominations MUST include (at minimum):
(1) A supporting letter from the Department Chair that documents the candidate's standing in his/her field.
(2) A one page personal statement by the candidate of his/her recent accomplishments and current research agenda.
(3) A Curriculum Vitae.
For more information please contact:
Sandra N. Smith
Grants Assistant
College of Medicine
Office for Research Affairs
Phone 392-5398
Fax 392-7427
snsmith@dean.med.ufl.edu (Posted 02/08/02)
(2) From the NIH Guide: NINDS POLICY UPDATE FOR CAREER (K) AWARDS (NOT-NS-02-008)
The National Institute of
Neurological Disorders and Stroke (NINDS) announces a change in the allowable salary
and research costs for its career award mechanisms. The mechanisms affected are the following (see: http://www.ninds.nih.gov/funding/research_training.htm).
o Mentored Research
Scientist Development Award (K01)
o Independent Scientist
Award (K02)
o Mentored Clinical
Scientist Development Award (K08)
o NINDS Career Transition
Award (K22)
o Mentored
Patient-Oriented Research Career Development Award (K23)
Effective with career awards
funded in FY 2002, all competing (Types 1) applications are eligible to request
the following higher salary and research costs:
o Maximum allowable
salary is $85,000.
o Maximum allowable
research costs for K01 awards is $35,000.
o Maximum allowable
research costs for K02, K08 and K23 awards is $50,000.
o Maximum allowable total
direct costs for the extramural phase of the K22 awards is $150,000; therefore,
applicants may request any combination of salary
(up to $85,000) and
research costs up to the maximum allowable direct costs.
This policy also applies
to all non-competing (Type 5) K02 awards.
However, the non-competing (Type 5) K01, K08, and K23 awards will
continue to receive salary and research support under the original terms and
conditions of the award.
INQUIRIES
Henry Khachaturian, Ph.D.
Research Training and
Career Development Officer
National Institute of
Neurological Disorders and Stroke
Neuroscience Center, Room
2154
6001 Executive Boulevard
Bethesda, MD 20892 (Courier Service: Rockville, MD 20852)
Telephone: (301) 496-4188
FAX: (301) 594-5929
Email: hk11b@nih.gov (Posted
02/08/02)
3) From the NIH Guide: NIMH POLICY UPDATE FOR CAREER AWARDS (K-SERIES) (NOT-MH-02-001)
This notice provides a
revision and update of the most recent NIMH POLICY UPDATE FOR CAREER AWARDS
(K-SERIES) that was published in the NIH Guide on June 12, 2000. This document is intended to complement
the policies of the Trans-NIH K-Series program announcements (see below). Prospective applicants must follow all
the instructions covered under each program announcement as well as the
Research Career Award section of PHS 398 when preparing
an application.
The purpose of this
notice is to address NIMH-specific issues regarding the following program
announcements:
·
PA-00-019: Mentored Research Scientist Development
Award (K01)
·
PA-00-020: Independent Scientist Award (K02)
·
PA-00-021: Senior Scientist Award (K05)
·
PA-00-003: Mentored Clinical Scientist Development
Award (K08)
·
PA-00-004: Mentored Patient-Oriented Research
Career Development Award (K23)
·
PA-00-005: Mid-Career Investigator Award in
Patient-Oriented Research (K24)
·
PA-99-087: Mentored Quantitative Research Career
Development Award (K25)
·
PAR-99-169: Scientist Development Award for New
Minority Faculty (K01)
·
PA-01-065: NIMH Research Career Award for Transition
to Independence (K22)
The notice covers
revisions and/or updates in regards to the following:
·
NIMH GENERAL POLICY ON
CAREER AWARDS
·
NIMH POLICY ON
ALLOWABLE COSTS
·
NIMH POLICY ON CHANGE
OF INSTITUTION
·
NIMH Staff Review
Consultation with NIMH
staff is encouraged especially during the planning phase of the
application. Prospective
applicants may visit the NIMH Research
Training and Career
Development Website: http://www.nimh.nih.gov/grants/training.cfm
to obtain additional information. (Posted 02/08/02)
4) From the NIH Guide: NOTICE REGARDING THE AVAILABILITY OF ADMINISTRATIVE SUPPLEMENTS TO SUPPORT INTERNATIONAL COLLABORATIVE RESEARCH ON DRUG ABUSE (NOT-DA-02-003)
The National Institute on Drug Abuse (NIDA) announces the availability of funds to supplement existing NIDA-supported research projects to expand current research efforts, within the scope of the original grant, to conduct research in international sites. Funds will be provided through administrative supplements to take advantage of unique opportunities to support research in all areas of drug-abuse science. Preference will be given to projects that are collaboratively funded by an agency of the host country. Only existing R01 and R21 grants supported by NIDA with at least one year of support remaining at the time of the supplemental award are eligible for supplemental support under this notice. Supplements may be requested for up to 2 years of support, but extend no longer than the parent
grant, with funding beginning no later than September 30, 2002. For more information refer to http://www.drugabuse.gov/Funding/Internationalsupp.html.
INQUIRIES
Inquiries concerning this notice are strongly encouraged. The opportunity to clarify any issue or questions from potential applicants is welcome.
Direct any questions about this notice to:
Steven Gust, Ph.D.
Acting Director, NIDA International Program
National Institute on Drug Abuse
6001 Executive Boulevard, Room 5274, MSC 9581
Bethesda, MD 20892-9581
Telephone: (301) 443-6480
Email: sgust@nida.nih.gov (Posted 02/08/02)
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»
1) The Burroughs Wellcome Fund is accepting applications for “Career Awards at the Scientific Interface”. Applications are due to ORA for an internal competition by April 8, 2002. Only two nominations will be accepted from each school. Contact ORA or Dr. Kirsten Madsen for an application or more information. For more information specific information or an application, go to Career Awards. (Posted 02/08/02)
2) The Pfizer Inc. is accepting applications for the “Atorvastatin Research Awards Program: A Focus on the Science”. Applications are due by March 15, 2002. (Posted 02/08/02)
3) The P.A. Foote Small Grants Program in Health Outcomes and Pharmacoeconomics Research is accepting proposals from University of Florida faculty, post-doctoral fellows, and graduate students for small grants to support the development of new research projects. Applications are due by April 19, 2002. Prospective applicants are encouraged to contact the program director, Abraham G. Hartzema, Ph.D., Perry A. Foote Eminent Scholar Chair in Health Outcomes Research and Pharmacoeconomics at 392-3871, or by e-mail at: Hartzema@cop.ufl.edu (Posted 02/08/02)
New NIH notices, requests for applications and program announcements can be found at NIH Notice (Posted 02/08/02)
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»
There is no new conference or
workshop information for this week.
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»
REMINDERS! (For Internal Competition Only)
There are no new reminders for this week.
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»§«¤»
CLOSING INFORMATION
Please send any comments or suggestions about this newsletter to Aundrea Corbit UNSUBSCRIBE:
If you do not want to receive any more issues, please reply to Aundrea Corbit with "REMOVE FROM ORA NEWSLETTER" in the subject line or body of the email.